요로감염증 환자에서 Carumonam의 효과 및 안전성에 관한 연구

Abstract

Carumonam, a new monobactam antibiotic obtained by chemical modification of a monocyclic β-lactam sulfazecin which produced by Pseudomonas acidophilia, was highly resistant to hydrolysis by β-lactamase and had strong antibacterial effect against gram negative bacilli. In our clinical strudy, Carumonam was administered intravenously 2.0g day in two divided doses to 31 patients with urinary tract infections. Clinical response was exallent in 11(35.4%), good in 13(42.0%), fair in 5(16.1%), and poor in 2(6.5%) patients. The overall efficacy was 77.4%. The adverse effect was observed in 2 cases, one was injection site pain and the other was transient leukopenia. Therefore we concluded that Carumonam was thought to be one of the effective antibiotics in urinary tract infections, and its adverse effects were minimal.